2018
DOI: 10.3389/fimmu.2018.01432
|View full text |Cite
|
Sign up to set email alerts
|

New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue

Abstract: Vaccines based on virus-like particles (VLPs) can induce potent B cell responses. Some non-chimeric VLP-based vaccines are highly successful licensed products (e.g., hepatitis B surface antigen VLPs as a hepatitis B virus vaccine). Chimeric VLPs are designed to take advantage of the VLP framework by decorating the VLP with a different antigen. Despite decades of effort, there have been few licensed chimeric VLP vaccines. Classic approaches to create chimeric VLPs are either genetic fusion or chemical conjugati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
140
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 125 publications
(142 citation statements)
references
References 126 publications
2
140
0
Order By: Relevance
“…VLPs were initially exploited for homologous vaccination [i.e., recombinant hepatitis B surface antigen (HBsAg) VLP vaccine protects against Hepatitis B virus, HPV L1 antigen VLP vaccine against Human papilloma virus (11,12)], and have been increasingly investigated also as carrier for heterologous antigens (13). Various techniques are available to decorate VLPs with the antigen(s) of interest [extensively reviewed by Brune and Howarth (14)], such as genetic fusion, chemical derivatization and conjugation, or plug-and-display decoration. This latter technique is based on the isopeptide bond that spontaneously forms between a peptide and its protein couple, derived from specific domains of certain bacterial proteins (15)(16)(17).…”
Section: Introductionmentioning
confidence: 99%
“…VLPs were initially exploited for homologous vaccination [i.e., recombinant hepatitis B surface antigen (HBsAg) VLP vaccine protects against Hepatitis B virus, HPV L1 antigen VLP vaccine against Human papilloma virus (11,12)], and have been increasingly investigated also as carrier for heterologous antigens (13). Various techniques are available to decorate VLPs with the antigen(s) of interest [extensively reviewed by Brune and Howarth (14)], such as genetic fusion, chemical derivatization and conjugation, or plug-and-display decoration. This latter technique is based on the isopeptide bond that spontaneously forms between a peptide and its protein couple, derived from specific domains of certain bacterial proteins (15)(16)(17).…”
Section: Introductionmentioning
confidence: 99%
“…In this case bacteria displayed the SpyTag that was available for binding to SpyCatcher-fused anti-GFP antibodies [96]. Of course, the method can be expanded by selecting nanobodies specific for other antigens and could be for instance used to decorate Virus Like-Particles with nanobodies suitable for improving their targeted delivery [97]. Nanobody display was exploited also for preparing Escherichia coli modified as tunable modular platforms for studying cell-cell adhesion and multicellular self-assembly [98].…”
Section: A De Marcomentioning
confidence: 99%
“…In addition, these technologies allow for separate recombinant production of antigens in various expression systems, ensuring high quality and correct protein processing before CLP conjugation [39][40][41][42]. The different conjugation systems used for modular CLP vaccine development is described in detail elsewhere [43]. Here, the main techniques are listed in Table 1 to provide a comparative overview of their relative practicality and ability to facilitate a high-quality epitope display.…”
Section: Modular Antigen Displaymentioning
confidence: 99%